ReviewAllergy, asthma & immunology research2024
Update on Inflammatory Biomarkers for Defining Asthma Phenotype.
Review in Allergy, asthma & immunology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Safety and effectiveness of benralizumab in Indian patients with severe eosinophilic asthma: results from the FAST study.Frontiers in medicine · 2026Trial
- The Adherence Paradox in Uncontrolled Moderate-To-Severe Asthma: A Qualitative Study of Patient Experiences and Unmet Needs.Research in nursing & health · 2026Article
- Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies.Current allergy and asthma reports · 2026Review
- Circulating Interleukin-17 Across Airway Disease Phenotypes: A Single-Center Observational Study.Journal of clinical medicine · 2026Article
- Clinical and immunologic features of adult primary antibody deficiency according to IVIGRT exposure.The Korean journal of internal medicine · 2026Article
- Integrated Immune, Epithelial and Lipid Pathways in NSAID-Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- Toward precision medicine in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.ERJ open research · 2026Article
- Cannabichromeorcin targets cathepsin L to alleviate oxidative stress-Driven airway inflammation in severe asthma.Redox biology · 2026Article
- Airway structural involvement detected by quantitative computed tomography in controlled and uncontrolled asthma.BMC pulmonary medicine · 2026Observational
- Predictive value of bronchoalveolar lavage fluid interleukin-25, interleukin-33, and thymic stromal lymphopoietin levels for asthma development in children with recurrent wheezing.BMC pediatrics · 2026Article
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Review
- Increased Levels of Serum Eosinophil-Derived Neurotoxin in Patients With Chronic Spontaneous Urticaria.Allergy, asthma & immunology research · 2026Article
- Targeting the Epithelial Alarmin Pathway with Tezepelumab in Highly Comorbid, Biologic-Experienced Severe Asthma: 52-Week Real-World Outcomes.Journal of clinical medicine · 2026Article
- Routine lipid profiles in allergic disease: a mini review.Frontiers in allergy · 2026Review
- A Functional Variant ofJournal of asthma and allergy · 2026Article
- Efficacy of Biologics on Nasal Symptoms in Severe Asthmatics: We Need Additional Biomarkers or Strategies to Assess Phenotypes or Endotypes.Allergy, asthma & immunology research · 2025Article
- Single-Cell Transcriptomic Profiling Reveals a Distinct Monocyte MIF/ANXA1 Signature Associated With Poor Responsiveness to ICS.Allergy, asthma & immunology research · 2025Article
- Distinct Roles Between Eotaxin 1 and Eotaxin 2 in Asthmatic Airways.Clinical and translational allergy · 2025Article
- Th2-High Severe Asthma with Hypereosinophilia in the Spectrum of Type 2 Inflammatory Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic heterogeneous disease characterized by various symptoms and persistent airway inflammation, resulting in progressive lung function decline. Classifying asthma phenotypes/endotypes is crucial because the underlying mechanisms and long-term outcomes vary from patient to patient. Recent trials have identified several biomarkers for classifying asthma phenotypes/endotypes, and current treatments have been developed on the basis of these biomarkers. Conventional biomarkers, including immunoglobulin E, blood/sputum eosinophil counts, airway obstruction or reversibility, and fractional exhaled nitric oxide, are widely used to diagnose asthma. However, these markers have some limitations, necessitating the discovery of additional biomarkers. Therefore, this review summarizes recently suggested biomarkers for representing type 2-high (eosinophilic) vs. type 2-low (neutrophilic) asthma, non-steroidal anti-inflammatory drug-exacerbated respiratory disease, and severe asthma. Additionally, we discuss the potential benefits of these biomarkers in classifying specific phenotypes/endotypes and managing asthmatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.